Mumbai, November 27 (Udaipur Kiran): Shares of Glenmark Pharmaceuticals were trading higher on the BSE after the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (USFDA) for its manufacturing facility in the USA. The stock was trading at Rs. 1,941.90, up by 20.95 points or 1.09 per cent from its previous close of Rs. 1,920.95.

The scrip opened at Rs. 1,934.95 and moved between a high of Rs. 1,958.00 and a low of Rs. 1,925.00 during the session. A total of 32,058 shares were traded on the counter so far.

The BSE Group ‘A’ stock, with a face value of Rs. 1, touched its 52-week high of Rs. 2,286.15 on July 11, 2025, and a 52-week low of Rs. 1,274.70 on February 28, 2025. Over the past one week, the stock moved between Rs. 1,825.00 and Rs. 1,958.00. The company’s current market capitalisation stands at Rs. 54,645.36 crore.

Promoters hold 46.65 per cent stake in the company, while institutional investors and non-institutional investors hold 39.38 per cent and 13.97 per cent respectively.

Glenmark Pharmaceuticals has received the Establishment Inspection Report with a Voluntary Action Indicated status from the USFDA for its formulations manufacturing facility located in Monroe, North Carolina, USA. The inspection was conducted by the agency from June 9 to June 17, 2025. Following this, commercial manufacturing at the Monroe facility will now restart.

Glenmark Pharmaceuticals is a global, research-led pharmaceutical company with presence across the generics, specialty and OTC segments, with operations in over 50 countries.

Related